Novel Therapies for Aggressive B-Cell Lymphoma

Table 2

Therapeutic antibodies in clinical development for the treatment of aggressive NHL. [CR: complete response; CRu: unconfirmed CR; DLBCL: diffuse large B-cell lymphoma; EFS: event-free survival; EOTR: extent of tumor resection; FL: follicular lymphoma; HL: Hodgkin lymphoma; mAb: monoclonal antibody; MCL: mantle cell lymphoma; mDR: median duration of response; MOA: mechanism of action; mPFS: median progression-free survival; MZL: marginal zone B-cell lymphoma; NHL: non-Hodgkin lymphoma; ORR: overall response rate; OS: overall survival; PFS: progression-free survival; PR: partial response; R-CHOP: cyclophosphamide, doxorubicin, vincristine, prednisolone plus rituximab; R: rituximab; R/R: relapsed or refractory; RR: response rate.]

Drug	MOA (target)	Eligibility (and design)	Phase	Randomized	Results
Ofatumumab [60]	Anti-CD20 mAb	R/R DLBCL	II	No	ORR: 11%; CR: 4%; mDR: 6.9 months; mPFS: 2.5 months
GA101 [67]	Anti-CD20 mAb	R/R DLBCL and MCL	II	Yes	EOTR: All: 28%; DLBCL: 29%; MCL: 27%
Veltuzumab [56]	Anti-CD20 mAb	R/R NHL	I/II	No	ORR: DLBCL: 43%; MZL: 83%, including CR/CRu: 33% ORR: FL: 44%, including CR/CRu: 27%
Epratuzumab [69]	Anti-CD22 mAb	R/R NHL (with rituximab)	II	No	ORR: 47%; DLBCL: CR: 33%
Epratuzumab [70]	Anti-CD22 mAb	Previously untreated DLBCL (with R-CHOP)	II	No	ORR: 95%; CR/CRu: 73%; 1-year EFS rate: 80%; 1-year PFS rate: 82%; 1-year OS rate: 88%
Milatuzumab [57]	Anti-CD74 mAb	R/R NHL (with veltuzumab)	I/II	Dose-finding	PR: 1/3 in Cohort 1 (8 mg/kg); 2/3 in Cohort 2 (16 mg/kg)
Dacetuzumab [77]	Anti-CD40 mAb	R/R DLBCL (with rituximab and gemcitabine)	Ib	Dose-finding	ORR: 54%
Lucatumumab [74]	Anti-CD40 mAb	R/R HL or NHL	Ia/II	Dose-finding	RR: R refractory: 40%; ORR: DLBCL: 11% (phase Ia); ORR: DLBCL: 15% (phase II)
Blinatumomab (MT103) [83]	Single-chain bispecific anti-CD19 and CD3 mAb construct	R/R NHL	I	Dose-finding	FL: 11/21 responses; MCL: 3/21 responses